Takeda’s dengue vaccine candidate suggest that it could help with outbreak prevention REPUBLIKA.CO.ID, JAKARTA Takeda Pharmaceutical Company Limited (Takeda) announced that its dengue vaccine candidate (TAK-003) demonstrated continued protection against dengue illness and hospitalization, regardless of an individual s previous dengue exposure, with no important safety risks identified through three years after vaccination in the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial. TIDES enrolled more than 20.000 healthy children and adolescents ages four to 16 years in dengue-endemic countries in Latin America and Asia. Dengue epidemics occur suddenly, and hospitals can become overwhelmed with severe disease cases and people seeking testing, said Managing Director Center for Clinical Management of Dengue and Dengue Haemorrhagic Fever, Negombo General Hospital, Sri Lanka and a primary investigator of the TIDES trial, LakKumar Fernando
Redirecting to Potential Impact of Takeda s Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results q8dailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from q8dailynews.com Daily Mail and Mail on Sunday newspapers.
Japan s Dengue Vaccine Candidate Demonstrated Long-Term Safety and Efficacy precisionvaccinations.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from precisionvaccinations.com Daily Mail and Mail on Sunday newspapers.
− Takeda's dengue vaccine candidate (TAK-003) prevented 83.6% of hospitalizations and 62.0% of dengue illness overall, with no identified important safety .